Skip to content

Annexon ANNX EPS (Diluted)

EPS (Diluted) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$6.75-7.2%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$0.85-3.7%
Vor Biopharma logo
Vor BiopharmaVOR
-$5.11+1.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$0.69+24.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$1.82+49.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's EPS (diluted)?
Annexon (ANNX) reported EPS (diluted) of -$0.23 in Q1 2026.
How has Annexon's EPS (diluted) changed year-over-year?
Annexon's EPS (diluted) increased by 37.8% year-over-year, from -$0.37 to -$0.23.
What is the long-term trend for Annexon's EPS (diluted)?
Over 4 years (2021 to 2025), Annexon's EPS (diluted) has grown at a -20.8% compound annual growth rate (CAGR), from -$3.40 to -$1.34.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.